PET Tracer Effective For CNS B-Cell Lymphoma Diagnosis

December 14th, 2020 | Technology

According to a proof-of-concept study, PET Tracer imaging with 68Ga-pentixafor is an effective diagnostic tool for central nervous system (CNS) B-cell lymphoma. 68Ga-pentixafor PET imaging shows excellent contrast characteristics between lymphoma lesions and surrounding healthy brain tissue. It may be suitable for risk stratification and response assessment by targeting the CXCR4 biomarker involved in the growth, survival, and dissemination of aggressive B-cell lymphoma.

CNS B-cell lymphoma is rare cancer with several clinical challenges, including diagnosis, risk stratification, and treatment optimization. While magnetic resonance imaging (MRI) is the current standard imaging technology for this disease, it only provides moderate specificity. For this patient population, novel molecular and functional imaging strategies are urgently needed.

CXCR4-directed PET tracer imaging with 68Ga-pentixafor could help with diagnostic work-up and response assessment and be used as a biomarker to identify patients with a poor prognosis who might benefit from more aggressive treatment options. CXCR4-targeted theranostics advances nuclear medicine toward biomarker-informed molecular medicine.

It is significant for patients with CNS B-cell lymphoma because CXCR4-directed PET imaging with 68Ga-pentixafor could help with diagnostic work-up and response assessment and be used as a biomarker to identify patients with a poor prognosis who might benefit from more aggressive treatment options. CXCR4-targeted theranostics advances nuclear medicine toward biomarker-informed molecular medicine.

Read more

Related Content: Hyperpolarizer – Quantum Cancer Imaging

Events & Shows

SPIE Optifab 2024
17 Oct – 19 Oct, 2024
Rochester, New York
Booth 1303

SPIE Photonics West 2025
28 Jan – 30 Jan, 2025
Rochester, New York
Booth 143

The Equal Employment Opportunity Clause required under Executive Order 11246, and the employee notice clause pertaining to employee rights under the National Labor Relations Act, set forth in 29 CFR Part 471 Appendix A to Subpart A, are incorporated by reference in this purchase order. By accepting this purchase order, vendor additionally certifies that, to the extent applicable, this contractor and subcontractor shall abide by the requirements of 41 CFR §§ 60-1.4(a), 60-300.5(a) and 60-741.5(a). These regulations prohibit discrimination against qualified individuals based on their status as protected veterans or individuals with disabilities and prohibit discrimination against all individuals based on their race, color, religion, sex, sexual orientation, gender identity, or national origin. Moreover, these regulations require that covered prime contractors and subcontractors take affirmative action to employ and advance in employment individuals without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status or disability, that it complies with the authorities cited above, and that it does not maintain segregated facilities or permit its employees to perform services at locations where segregated facilities are maintained, as required by 41 CFR 60-1.8.